Lpath to Present at 34th Annual Canaccord Genuity Growth Conference

SAN DIEGO, Aug. 11, 2014 /PRNewswire/ -- Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, today announced that Scott Pancoast, president and CEO, will present at the 34th Annual Canaccord Genuity Growth Conference on Wednesday, August 13, 2014 at 5:00 p.m. Eastern Time in Boston. The live webcast presentation and replay will be available by visiting the Investor section of the Lpath website at www.Lpath.com.

About Lpath
San Diego-based Lpath, Inc. (NASDAQ: LPTN), an antibody-platform company, is the category leader in lipid-targeted therapeutics. The company's ImmuneY2™ drug-discovery engine has the unique ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to disease. The company has developed four drug candidates, two of which – iSONEP™ for wet AMD and ASONEP™ for cancer—are currently being investigated in Phase 2 trials. The other candidates are an anti-lysophosphatidic acid antibody, Lpathomab^TM, which is expected to enter the clinic in 2015 for neuropathic pain and neurotrauma, and an anti-leukotriene antibody, Altepan^TM, which is being studied in models of respiratory disease. For more information, visit www.Lpath.com.

SOURCE Lpath